Immunogenic HbsAg derived from transformed yeast
US4707542A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 1, 1984 |
| Grant date | Nov 17, 1987 |
| Priority date | — |
| Expiry date | Aug 1, 2004 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/826
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The surface antigen protein of human Hepatitis B virus is synthesized in Saccharomyces cerevisiae as a 23,000-26,000 dalton polypeptide, essentially free of intermolecular disulfide bonds. This antigen is a poor immunogen in animals and man. No prior precedent or method exists for efficiently converting the non-disulfide bonded antigen to a fully intermolecular disulfide bonded particle. We describe the first example of such a conversion in vitro and show that the act of this conversion enhances the immunogenicity of the antigen about 10-fold. The in vitro conversion makes practical the production of hepatitis B surface antigen from microorganisms using recombinant DNA methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.